Partnership to accelerate development of IND candidates from tRNA synthetases in aTyr’s pipeline
aTyr eligible to receive up to $17 million in potential option fees
SAN DIEGO, CA, USA I March 11, 2019 I aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a research collaboration and option agreement with global biotherapeutics leader CSL Behring, for the development of product candidates derived from up to four tRNA synthetases from aTyr’s preclinical pipeline.
“This research collaboration with CSL Behring, an industry leader in the development of plasma-derived and recombinant therapeutics for rare and serious diseases, represents an important validation of our science and enables us to accelerate development of potential IND candidates from our pipeline,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr. “We believe the combination of our discovery pipeline and knowledge of tRNA synthetases and CSL Behring’s expertise in drug development will yield innovative immunological therapies, and we look forward to a long and mutually beneficial partnership.”
Under the terms of the collaboration, CSL Behring will fund all research and development activities related to the development of the applicable product candidates for the duration of the collaboration. CSL Behring will pay a total of up to $4.25 million per synthetase program ($17 million if all four synthetase programs advance) in option fees based on achievement of research milestones and CSL Behring’s determination to continue development. In addition, aTyr will grant CSL Behring an option to negotiate licenses for worldwide rights to each IND candidate that emerges from this research collaboration. Specific license terms will be negotiated during an exclusivity period following the exercise of each program option.
CSL Behring is a global biotherapeutics leader specializing in immunology, hematology and other rare and serious medical conditions. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes. aTyr is focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family. ATYR1923 is a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases and other immune-mediated diseases. For more information, please visit http://www.atyrpharma.com.
SOURCE: aTyr
Post Views: 167
Partnership to accelerate development of IND candidates from tRNA synthetases in aTyr’s pipeline
aTyr eligible to receive up to $17 million in potential option fees
SAN DIEGO, CA, USA I March 11, 2019 I aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a research collaboration and option agreement with global biotherapeutics leader CSL Behring, for the development of product candidates derived from up to four tRNA synthetases from aTyr’s preclinical pipeline.
“This research collaboration with CSL Behring, an industry leader in the development of plasma-derived and recombinant therapeutics for rare and serious diseases, represents an important validation of our science and enables us to accelerate development of potential IND candidates from our pipeline,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr. “We believe the combination of our discovery pipeline and knowledge of tRNA synthetases and CSL Behring’s expertise in drug development will yield innovative immunological therapies, and we look forward to a long and mutually beneficial partnership.”
Under the terms of the collaboration, CSL Behring will fund all research and development activities related to the development of the applicable product candidates for the duration of the collaboration. CSL Behring will pay a total of up to $4.25 million per synthetase program ($17 million if all four synthetase programs advance) in option fees based on achievement of research milestones and CSL Behring’s determination to continue development. In addition, aTyr will grant CSL Behring an option to negotiate licenses for worldwide rights to each IND candidate that emerges from this research collaboration. Specific license terms will be negotiated during an exclusivity period following the exercise of each program option.
CSL Behring is a global biotherapeutics leader specializing in immunology, hematology and other rare and serious medical conditions. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes. aTyr is focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family. ATYR1923 is a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases and other immune-mediated diseases. For more information, please visit http://www.atyrpharma.com.
SOURCE: aTyr
Post Views: 167
